ACOSOG is a cooperative group comprised of practicing medical, radiation, and surgical oncologists, diagnostic imagers, patient advocates, pathologists, basic scientists, nurses/CRAs, statisticians, and other healthcare professionals representing academic and community practices throughout the U.S. The purpose of ACOSOG is to develop and evaluate innovative cancer therapies in which the surgical management of cancer patients plays a key role. ACOSOG Is dedicated to Improving the care of the surgical oncology patient through an Innovative clinical research program addressing three specific aims: 1. To test novel therapies that may increase response and cure rates and reduce morbidities and disabilities associated with cancer care 2. To conduct basic science studies in conjunction with clinical trials to better understand the biologic basis of diseases and treatments. 3. To support Individual members and investigator networks to accrue patients to trials and fulfill the scientific mission of ACOSOG. The scientific portfolio of ACOSOG is focused on investigations addressing three scientific aims for ACOSOG trials: 1) to investigate novel surgical and targeted therapies to maintain oncologic outcomes while reducing toxicities and disabilities and Improving quality of life;2) to enhance the accuracy of risk stratification through imaging and molecular profiling;and 3) to Improve overall response rates and monitor Individual responses through the application of neoadjuvant therapies. The scientific agenda is established by the Basic and Translational Science Committee and the three Disease Committees: Breast, Gastrointestinal (GIST, pancreas, and rectum), and Thoracic (lung and esophagus) and maintained and prioritized by the ACOSOG Peer Review Committees. A multidisciplinary approach to the scientific agenda is accomplished through the comprehensive integration of all modalities and disciplines. Membership interests, needs, and oversight are attended to through the actions of seven Administrative Committees. To accomplish the goals of ACOSOG, the group conducts clinical trials and correlative studies using an infrastructure consisting of three critical components Including: 1) the Operations and Membership Center (OMC) located in Durham, NC, within the Duke Clinical Research Institute;2) the Statistics and Data Center (SDC) located In Rochester, MN, within the Mayo Clinic Cancer Center;and 3) the Central Specimen Bank (U24 # 5 U24 CA114736) located in St. Louis, MO, within the Washington University.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
7U10CA076001-16
Application #
8253693
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1998-05-15
Project End
2013-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
16
Fiscal Year
2012
Total Cost
$2,940,780
Indirect Cost
$366,279
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Boughey, Judy C; Ballman, Karla V; Le-Petross, Huong T et al. (2016) Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance) Ann Surg 263:802-7
Brown, Paul D; Jaeckle, Kurt; Ballman, Karla V et al. (2016) Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA 316:401-9
Haffty, Bruce G; McCall, Linda M; Ballman, Karla V et al. (2016) Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance). Int J Radiat Oncol Biol Phys 94:493-502
Kent, Michael S; Mandrekar, Sumithra J; Landreneau, Rodney et al. (2016) Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance). Ann Thorac Surg 102:230-8
Miller, Christopher A; Gindin, Yevgeniy; Lu, Charles et al. (2016) Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun 7:12498
Boughey, Judy C; Suman, Vera J; Mittendorf, Elizabeth A et al. (2015) Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg 261:547-52
Fernando, Hiran C; Landreneau, Rodney J; Mandrekar, Sumithra J et al. (2015) Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: results from the ACOSOG Z4032 (Alliance) multicenter randomized trial. J Thorac Cardiovasc Surg 149:718-25; discussion 725-6
Garcia-Aguilar, Julio; Renfro, Lindsay A; Chow, Oliver S et al. (2015) Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol 16:1537-46
Boughey, Judy C; Ballman, Karla V; Hunt, Kelly K et al. (2015) Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol 33:3386-93
Dupuy, Damian E; Fernando, Hiran C; Hillman, Shauna et al. (2015) Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial. Cancer 121:3491-8

Showing the most recent 10 out of 62 publications